vs

Side-by-side financial comparison of Opera Ltd (OPRA) and PROCEPT BioRobotics Corp (PRCT). Click either name above to swap in a different company.

Opera Ltd is the larger business by last-quarter revenue ($142.7M vs $83.1M, roughly 1.7× PROCEPT BioRobotics Corp). Opera Ltd runs the higher net margin — 12.8% vs -38.1%, a 50.9% gap on every dollar of revenue.

Opera is a multinational technology corporation headquartered in Oslo, Norway, with additional offices in Europe, China, and Africa. Opera offers a range of products and services that include PC and mobile web browsers, GameMaker and gaming portals, the Opera News content recommendation products, the Opera Ads platform, and a number of Web3 and e-commerce products and services. The company's total user base is 296 million monthly active users.

PROCEPT BioRobotics Corp is a medical tech firm developing and commercializing robotic surgical solutions for urological care. Its flagship AquaBeam system provides image-guided minimally invasive therapy for benign prostatic hyperplasia, serving providers and patients across North America, Europe and global markets.

OPRA vs PRCT — Head-to-Head

Bigger by revenue
OPRA
OPRA
1.7× larger
OPRA
$142.7M
$83.1M
PRCT
Higher net margin
OPRA
OPRA
50.9% more per $
OPRA
12.8%
-38.1%
PRCT

Income Statement — Q1 FY2025 vs Q1 FY2026

Metric
OPRA
OPRA
PRCT
PRCT
Revenue
$142.7M
$83.1M
Net Profit
$18.3M
$-31.6M
Gross Margin
64.9%
Operating Margin
14.8%
-4.1%
Net Margin
12.8%
-38.1%
Revenue YoY
20.2%
Net Profit YoY
-27.9%
EPS (diluted)
$-0.56

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
OPRA
OPRA
PRCT
PRCT
Q1 26
$83.1M
Q4 25
$76.4M
Q3 25
$83.3M
Q2 25
$79.2M
Q1 25
$142.7M
$69.2M
Q4 24
$68.2M
Q3 24
$58.4M
Q2 24
$211.6M
$53.4M
Net Profit
OPRA
OPRA
PRCT
PRCT
Q1 26
$-31.6M
Q4 25
$-29.8M
Q3 25
$-21.4M
Q2 25
$-19.6M
Q1 25
$18.3M
$-24.7M
Q4 24
$-18.9M
Q3 24
$-21.0M
Q2 24
$34.1M
$-25.6M
Gross Margin
OPRA
OPRA
PRCT
PRCT
Q1 26
64.9%
Q4 25
60.6%
Q3 25
64.8%
Q2 25
65.4%
Q1 25
63.9%
Q4 24
64.0%
Q3 24
63.2%
Q2 24
59.0%
Operating Margin
OPRA
OPRA
PRCT
PRCT
Q1 26
-4.1%
Q4 25
-40.6%
Q3 25
-27.8%
Q2 25
-28.0%
Q1 25
14.8%
-39.7%
Q4 24
-28.9%
Q3 24
-38.4%
Q2 24
19.6%
-50.3%
Net Margin
OPRA
OPRA
PRCT
PRCT
Q1 26
-38.1%
Q4 25
-39.1%
Q3 25
-25.7%
Q2 25
-24.7%
Q1 25
12.8%
-35.8%
Q4 24
-27.6%
Q3 24
-35.9%
Q2 24
16.1%
-48.0%
EPS (diluted)
OPRA
OPRA
PRCT
PRCT
Q1 26
$-0.56
Q4 25
$-0.54
Q3 25
$-0.38
Q2 25
$-0.35
Q1 25
$-0.45
Q4 24
$-0.34
Q3 24
$-0.40
Q2 24
$-0.50

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
OPRA
OPRA
PRCT
PRCT
Cash + ST InvestmentsLiquidity on hand
$245.6M
Total DebtLower is stronger
$51.7M
Stockholders' EquityBook value
$347.7M
Total Assets
$487.1M
Debt / EquityLower = less leverage
0.15×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
OPRA
OPRA
PRCT
PRCT
Q1 26
$245.6M
Q4 25
$286.5M
Q3 25
$294.3M
Q2 25
$302.7M
Q1 25
$316.2M
Q4 24
$333.7M
Q3 24
$196.8M
Q2 24
$214.1M
Total Debt
OPRA
OPRA
PRCT
PRCT
Q1 26
$51.7M
Q4 25
$51.6M
Q3 25
$51.6M
Q2 25
$51.5M
Q1 25
$51.5M
Q4 24
$51.5M
Q3 24
$51.4M
Q2 24
$51.4M
Stockholders' Equity
OPRA
OPRA
PRCT
PRCT
Q1 26
$347.7M
Q4 25
$365.9M
Q3 25
$380.3M
Q2 25
$385.8M
Q1 25
$389.2M
Q4 24
$402.2M
Q3 24
$241.2M
Q2 24
$251.8M
Total Assets
OPRA
OPRA
PRCT
PRCT
Q1 26
$487.1M
Q4 25
$508.1M
Q3 25
$511.5M
Q2 25
$513.1M
Q1 25
$519.4M
Q4 24
$534.0M
Q3 24
$374.1M
Q2 24
$374.4M
Debt / Equity
OPRA
OPRA
PRCT
PRCT
Q1 26
0.15×
Q4 25
0.14×
Q3 25
0.14×
Q2 25
0.13×
Q1 25
0.13×
Q4 24
0.13×
Q3 24
0.21×
Q2 24
0.20×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

OPRA
OPRA

Segment breakdown not available.

PRCT
PRCT

Handpieces and other consumables$43.0M52%
System sales and rentals$23.4M28%
Other$11.1M13%
Service$5.6M7%

Related Comparisons